Jpmorgan Chase & CO Lineage Cell Therapeutics, Inc. Transaction History

Jpmorgan Chase & CO

  • $1.22 Trillion
  • Q3 2024

A detailed history of Jpmorgan Chase & CO transactions in Lineage Cell Therapeutics, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 677,162 shares of LCTX stock, worth $419,840. This represents 0.0% of its overall portfolio holdings.

Number of Shares
677,162
Previous 594,298 13.94%
Holding current value
$419,840
Previous $594,000 3.7%
% of portfolio
0.0%
Previous 0.0%

Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Dec 26, 2024
BUY
$0.8 - $1.12 $66,291 - $92,807
82,864 Added 13.94%
677,162 $616,000
Q3 2024

Nov 08, 2024
BUY
$0.8 - $1.12 $66,291 - $92,807
82,864 Added 13.94%
677,162 $616,000
Q2 2024

Dec 26, 2024
SELL
$0.89 - $1.47 $73,748 - $121,810
-82,864 Reduced 12.24%
594,298 $594,000
Q2 2024

Aug 12, 2024
SELL
$0.89 - $1.47 $72,451 - $119,666
-81,406 Reduced 12.05%
594,298 $594,000
Q1 2024

Dec 26, 2024
SELL
$0.86 - $1.48 $1,253 - $2,157
-1,458 Reduced 0.22%
675,704 $1 Million
Q1 2024

May 10, 2024
SELL
$0.86 - $1.48 $44,125 - $75,937
-51,309 Reduced 7.06%
675,704 $1 Million
Q4 2023

Dec 26, 2024
BUY
$0.91 - $1.35 $45,364 - $67,298
49,851 Added 7.36%
727,013 $792,000
Q4 2023

Feb 12, 2024
BUY
$0.91 - $1.35 $15,956 - $23,672
17,535 Added 2.47%
727,013 $792,000
Q3 2023

Nov 14, 2023
SELL
$1.16 - $1.53 $383,970 - $506,443
-331,009 Reduced 31.81%
709,478 $837,000
Q2 2023

Aug 11, 2023
SELL
$1.26 - $1.53 $90,246 - $109,584
-71,624 Reduced 6.44%
1,040,487 $1.47 Million
Q1 2023

May 11, 2023
BUY
$1.2 - $1.53 $28,238 - $36,003
23,532 Added 2.16%
1,112,111 $1.67 Million
Q4 2022

Feb 13, 2023
BUY
$1.02 - $1.5 $40,318 - $59,292
39,528 Added 3.77%
1,088,579 $1.27 Million
Q3 2022

Nov 14, 2022
SELL
$1.13 - $1.77 $234,905 - $367,949
-207,881 Reduced 16.54%
1,049,051 $1.19 Million
Q2 2022

Aug 11, 2022
SELL
$1.12 - $1.61 $663,857 - $954,295
-592,730 Reduced 32.05%
1,256,932 $1.99 Million
Q1 2022

May 11, 2022
BUY
$1.21 - $2.48 $685,325 - $1.4 Million
566,385 Added 44.14%
1,849,662 $2.85 Million
Q4 2021

Feb 10, 2022
SELL
$1.84 - $2.68 $1.72 Million - $2.5 Million
-932,515 Reduced 42.08%
1,283,277 $3.15 Million
Q3 2021

Nov 12, 2021
BUY
$2.26 - $2.86 $5.01 Million - $6.34 Million
2,215,792 New
2,215,792 $5.58 Million

Others Institutions Holding LCTX

# of Institutions
121
Shares Held
95.1M
Call Options Held
63.8K
Put Options Held
1K
View Full List

About Lineage Cell Therapeutics, Inc.

LCTX Quotes by TradingView
  • Ticker LCTX
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 169,755,008
  • Market Cap $105M
  • Description
  • Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...
More about LCTX
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email